Fallopian tube malignant mixed müllerian tumor (carcinosarcoma): a case report with immunohistochemical profiling

We report a case of malignant mixed mullerian tumor (MMMT) (carcinosarcoma) of the right fallopian tube in a 69-year-old woman presenting with abdominal pain and an adnexal mass. The patient underwent total abdominal hysterectomy. bilateral salpingo-oophorectomy, omentectomy, received adjuvant chemotherapy and is without evidence of disease 12 months postoperatively. The tumor involved the fallopian tube and was composed of in situ and invasive high-grade serous and undifferentiated carcinoma. leiomyosarcoma, rhabdomyosarcoma and undifferentiated sarcoma. Immunohistochemically, the epithelial and mesenchymal cells expressed CD56. Leu-7 and p53. The epithelial elements expressed nuclear WT1 and calretinin while the mesenchymal cells showed negative nuclear and strong cytoplasmic staining. HBME was observed focally in carcinoma. The expression of mesothelial-associated antigens WT1, calretinin and HBME in MMMT likely reflects the common embryologic derivation of the mesothelium and urogenital ridge. Loss of nuclear WT1 expression in the mesenchymal component may be involved in MMMT tumorigenesis.

Fallopian tube; Carcinosarcoma; Malignant mixed müllerian tumor (MMMT); Immunohistochemistry; WT1

[1] Carlson J.A., Ackerman B.L., Wheeler J.E.: “Malignant mixed müllerian tumor of the fallopian tube”. Cancer, 1993, 71, 187.

[2] Scully R.E., Young R.H., Clement P.B.: “Tumors of the fallopian tube: Histologic classification and cancer staging epithelial and mixed epithelial-mesenchymal tumors”. In: Rosai J., Sobin L.H. (eds.). Atlas of Tumor Pathology: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Third series. Armed Forces Institute of Pathology, Washington, D.C., 1998, 457.

[3] Saleh E.R.M., Franca C.M., Marques M.M.: “Neural adhesion molecule (N-CAM) in pleomorphic adenoma and carcinoma expleomorphic adenoma”. J. Oral. Pathol. Med., 2003, 32, 562.

[4] George E., Manivei C., Dehner L.P., Wick M.R.: “Malignant mixed müllerian tumors: An immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation”. Hum. Pathol., 1991, 21, 215.

[5] Amant F., Moerman P., Davel G.H., De Vos R., Vergote I., Lindesque B.G., de Jonge E.: “Uterine carcinosarcoma with melanocytic differentiation”. Int. J. Gynecol. Pathol., 2001, 20, 186.

[6] Kuroda N., Moriki T., Oguri H., Maeda N., Toi M., Miyazaki E. et al.: “Malignant mixed müllerian tumor (carcinosarcoma) of the fallopian tube: an immunohistochemical study of neoplastic cells”. APMIS, 2005, 113, 643.

[7] Alvarado-Cabrero I., Cheung A., Caduff R.: “Tumors of the fallopian tube”. In: Tavassoli F.A., Devilee P. (eds.). World Health Organization Classification of Tumours. Pathology and Genetics: Tumors of the Breast and female genital organs. Lyon, France, IARC Press, 2003, 210.

[8] Costa M.J., Vogelsan J.,Young L.J.: “p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases”. Mod. Pathol., 1994, 7, 619.

[9] Kounelis S., Jones M.W., Papadaki H., Bakker A., Swalsky P., Finkelstein S.D.: “Carcinosarcomas (malignant mixed müllerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components”. Hum. Pathol., 1998, 29, 82.

[10] Pritchard-Jones K., Fleming S., Davidson D., Bickmore W., Porteus D., Bard J. et al.: “The candidate Wilm’s tumour gene is involved in the genitourinary development”. Nature, 1990;346:194-197.

[11] Amin K.M., Litzky L.A., Smythe W.R., Mooney A.M., Morris J.M. et al.: “Wilms’ tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma”. Am. J. Pathol., 1995, 146, 344.

[12] Acs G., Pasha T., Zhang P.J.: “WT1 is differentially expressed in serous endometrioid clear cellvand mucinous carcinomas of the peritoneum, fallopian tube, ovary and endometrium”. Int. J. Gynecol. Pathol., 2004, 23, 110.

[13] Kumar-Singh S., Segers K., Rodeck U., Backhovens H., Bogers J., Weyler J. et al.: “WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis”. J. Pathol., 1997, 181, 67.

[14] Kourea H.P., Cordon-Cardo C., Dudas M., Leung D., Woodruff J.M.: “Expression of p27/kip and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas. The emerging role of p27 in malignant transformation of neurofibromas”. Am. J. Pathol., 1999, 155, 1885.

[15] Viglietto G., Motti M.L., Bruni P., Melillo R.M., D’Alessio A., Califano D. et al.: “Cytoplasmic relocalization and inhibition of cyclin-dependent kinase inhibitor p27(kip1) by PKB/Akt-mediated phosphorylation in breast cancer”. Nat. Med., 2002, 8, 1136.